Newsletter | May 21, 2025

05.21.25 -- A Better Way For BD And Commercial Teams To Evaluate Strategic Assets

NEW PODCAST EPISODE

Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.

Hear how BioCardia is advancing cardiac and pulmonary cell therapies. CEO Peter Altman, Ph.D., joins Cell & Gene: The Podcast to discuss precision medicine, the CardiAMP program, and the roadblocks to FDA approval. Tune in for insights on clinical strategy, trial design, and what's next for this evolving biotech.

FEATURED ARTICLE

A Better Way For BD And Commercial Teams To Evaluate Strategic Assets

To unlock value and avoid costly mistakes, life sciences BD teams must work with commercial teams to help evaluate potential deals, before key assumptions are locked in, writes Ardelyx's Shetal Vyas.

INDUSTRY INSIGHTS

The Strategic Role Of KOLs In Rare Disease Drug Development

Strategic Key Opinion Leader (KOL) engagement is crucial for accelerating innovation in trials. However, identifying the right experts is challenging due to fragmented data and evolving expertise.

Why An Integrated Approach Ensures Smooth Entry Into The EU Market

Simplify your European launch and boost returns. Learn how to manage regulatory hurdles, access a huge patient population, and gain end-to-end commercial support.

Key To A Faster, More Flexible Clinical Trial Process

Discover how a single, integrated data analytics and visualization platform, supported by an experienced partner, can help you move your investigational product to market more quickly.

From Nanoformed Powder To 3D Printable Ink

3D printing in pharmaceutics is advancing to offer innovative drug delivery applications. Explore the possibilities of forming stable suspension in printing ink from nanoformed materials.

GSK And Medable Discuss The Next Phase Of DCTs

GSK and Medable share the value of embedding decentralized clinical trials into strategic goals to enhance trial accessibility, diversity, and efficiency.